Lidocain Pharmarissano (Lidocaine Hydrochloride)

• Lidocaine is used in the local anesthetic class to block nerve conduction in various procedural settings.
• Minor surgical procedures: provides localized numbness to facilitate painless incision and suturing.
• Acute pain management: delivers regional anesthesia to reduce pain perception during short‑term interventions.
• Regional anesthesia: employed for nerve block techniques to anesthetize specific body regions.

• Lidocaine blocks voltage‑gated sodium channels on neuronal membranes, stabilizing the inactive state of the channel and preventing the rapid influx of sodium ions required for depolarization. This inhibition halts the initiation and propagation of nerve impulses, resulting in reversible loss of sensation in the targeted area without affecting surrounding tissues.

Lidocaine may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects

• Transient burning or tingling at the injection site
• Mild dizziness or light‑headedness
• Nausea or vomiting
• Metallic taste in the mouth

Serious or Rare Side Effects

• Systemic toxicity presenting as seizures, cardiac arrhythmias, or respiratory depression
• Allergic reactions such as urticaria, angioedema, or anaphylaxis
• Methemoglobinemia, a rare blood disorder causing reduced oxygen delivery

• When using Lidocain Pharmarissano, clinicians should observe several precautionary measures to ensure patient safety.
• Allergy assessment: confirm no known hypersensitivity to amide‑type local anesthetics.
• Cardiovascular status: avoid rapid intravenous bolus in patients with conduction abnormalities or severe heart disease.
• Maximum dose adherence: respect the recommended total dose limits for the chosen route of administration.
• Concurrent CNS depressants: monitor for additive sedative effects when combined with other central nervous system depressants.
• Pregnancy and lactation: consider use only when the potential benefit justifies the potential risk to the fetus or infant.
• Store below 25°C: keep in the original container, protect from moisture and light.

Lidocaine can interact with several medicines, altering its plasma concentration or enhancing pharmacodynamic effects.

Major Interactions (Avoid)

• Class I antiarrhythmic agents (e.g., quinidine, procainamide): may increase lidocaine levels and risk of cardiotoxicity.
• Strong CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): can raise systemic exposure.
• Beta‑adrenergic blockers: may potentiate cardiac conduction effects.
• High‑dose general anesthetics (e.g., propofol, volatile agents): additive central nervous system depression.

Moderate Interactions (Monitor Closely)

• CYP1A2 inducers (e.g., rifampin, carbamazepine): may reduce lidocaine effectiveness.
• Non‑steroidal anti‑inflammatory drugs: may increase bleeding tendency when combined with regional techniques.
• Diuretics: can alter plasma protein binding, modestly affecting lidocaine concentration.
• Alcohol: enhances sedative properties and may increase risk of CNS depression.